Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.00 is 100% below its 5-year average of 0.02, near the low end of its 5-year range (0.00–0.13).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
0.02
DEBT TO EQUITY RATIO AVG 10Y
0.00
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 467 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Adial Pharmaceuticals, Inc.
Market Cap
$11.65M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.02
Market Cap
$11.39M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.01
Market Cap
$11.21M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.02
Market Cap
$12.07M
Debt to Equity Ratio
N/A
TTM Avg
3.67
3Y Avg
2.17
5Y Avg
1.48
Market Cap
$10.86M
Debt to Equity Ratio
0.09
TTM Avg
0.06
3Y Avg
1.84
5Y Avg
2.48
Market Cap
$10.68M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adial Pharmaceuticals, Inc. (ADIL) | $11.65M | 0.00 | 0.00 | 0.00 | 0.02 |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.39M | 0.00 | 0.00 | 0.00 | 0.01 |
| Cerenome, Inc. (CNSY)vs › | $11.29M | 0.01 | 0.21 | 0.55 | 1.02 |
| Biofrontera Inc. (BFRI)vs › | $11.27M | 1.26 | 0.85 | 0.72 | 0.48 |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.21M | 0.02 | 0.01 | 0.01 | 0.02 |
| BioVie Inc. (BIVI)vs › | $11.09M | 0.03 | 0.03 | 0.35 | 0.79 |
| Cytosorbents Corporation (CTSO)vs › | $12.07M | N/A | 3.67 | 2.17 | 1.48 |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.86M | 0.09 | 0.06 | 1.84 | 2.48 |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $10.68M | 0.01 | 0.00 | 0.00 | 0.00 |
| IRIDEX Corporation (IRIX)vs › | $12.70M | 1.10 | 0.92 | 1.14 | 0.73 |
Debt/Equity
0.00
Current Ratio
5.63
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.00 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.13 |
| 2022-12-31 | 0.06 |
| 2022-09-30 | 0.04 |
| 2022-06-30 | 0.03 |
| 2022-03-31 | 0.02 |
| 2021-12-31 | 0.07 |
| 2021-09-30 | 0.04 |
| 2021-06-30 | 0.06 |
| 2021-03-31 | 0.06 |
| 2020-12-31 | 0.00 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.00 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.03 |
| 2018-06-30 | -0.77 |
| 2018-03-31 | -0.74 |
| 2017-12-31 | -0.69 |
| 2017-09-30 | -0.78 |
| 2017-06-30 | -1.07 |
| 2017-03-31 | -0.96 |
| 2016-12-31 | -2.26 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
